Abstract t1nconlrolled Graves' disease in pregnant women might result in abnormalities of the development and growth of the fetus-Once becoming eurhyT,ifl on anfithyroiâ drug, the pregnancy might ensue toward lerm and normal delivery. Overtreatment however, mighl caure piobleris to the baby iuch as hl,pothyroidism and goitre, resulting in dfficulties at the delivery and growth problems ldter in their life. Evaluation on the outcom"'ol pr"gnor"y and the delivered babies among pregnant Graves' women wcts conducled. All the pregnànt Graves, mother attended oru: ihyioid ilini" *rr" treated with PTU, the dose were tailored according to' lhe levels of Ta / -FTt and TSH of the pregnant mother. Laboratory evaluation was done every ntonlh from lhe slarl of pregnancy up to the time of delivery, during which thT.fetus TSH from the umbilical cord blood and the mother's serum TRab were also measured. There were altogether l2 pregnant Graves' u,omen completed their pregtrcncy during the year 1997. Some pregnancy ended with low SC due to gtnîcobgic iiaiùnn. All the babies born in this series *,ere normal, without apparent congenital anomalies. The mean birthweight, iearl raté, TSH and TRob levels were 3053 ! 279 grams, 14.5 + 8.4 beat/minute, 6.4 + 6.7 ug/L respeclively. The mean serum TRab of the mother were l8.7ok. The average ronl dose of PTU during pregnancy was 200-300 tablets of 50 mg. There was signif;cant correiation between the amount of PTÙ tublets consumed during the pregnancy and the levels of the umbilical cord blood THS level, but there was no corelation between the TRab and TSH levels of the born babies. It was concluded that the use of PTU among pregnonl Graves' women, in conjunction with meticulous moniloring of pregwncy and thyroid function resulted in sde outcome of pregnancy.
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PTU was given between 201-300 tablets. PTU was given between 301-400 tablets.
PTU was given between 401-500 tablets. PTU was given above 500 tablets.
Data processing
The collected data were included in the case record form, tabulated according to the aims of the study.
There after they were edited, coded, and stored in the hard disk using IBM compatible personal computer with the help of software SPSS for window release 6.0 and presented in table and graphic form.
Multivariate analysis was performed to find out the correlation between fetal TSH and pTU total dose, as well as mother's TSH receptor antibody at delivery.
RESULT Table I lists the characteristics of the 12 subjects (mothers and neonates) included in this study. 
